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Background
Therapeutic immunoconjugates consist of
a specifically tumor-targeting antibody
covalently linked or chelated to a toxic
effector molecule. They can be catego-
rized into three groups defined by the
nature of the “effector” molecule; that is,
when the effector is an isotope, the conju-
gate is referred to as a radioimmunocon-
jugate (RIC); when the effector is a protein
toxin, the conjugate is an immunotoxin
conjugate (ITC); and when the effector is
a small drug, the conjugate is an anti-
body-drug conjugate or tumor-activated
prodrug (TAP) (Blättler et al., 1996).
The initial phases of immunoconju-
gate chemotherapeutic development
proved to be disappointing due to several
factors which were not appreciated at first
(Blättler and Chari, 2001). It was hoped
that the conjugation of clinically useful
anticancer drugs to antibodies would
result in targeted therapeutics with fewer
toxic side effects than with the free drug.
However, the pharmacokinetics and
pharmacodynamics of the antibody-
linked drug mirrored those of the uncon-
jugated antibody, resulting in essentially
no efficacy, and toxicities similar to those
seen with free drug. Eventually, it was
understood that to achieve a therapeutic
window with immunoconjugates, the
effector molecule had to be cytotoxic in
the picomolar range similar to the antigen
binding avidities of the antibodies. Thus,
many attempts to create conjugates of
antibodies to highly toxic bacterial and
plant toxins such as pseudomonus exo-
toxin, diphtheria toxin, ricin, gelonin,
saporin, and pokeweed antiviral protein
(PAP) were undertaken (Kreitman, 2001).
While immunotoxins proved to be highly
efficacious in specifically killing tumor
cells in vitro and showed antitumor activi-
ty in xenograft models, in humans they
proved highly immunogenic, inducing
neutralizing antibodies targeting both the
toxin protein and mouse monoclonal anti-
body epitopes (Kreitman, 2001). To over-
come this difficulty, the next generation of
immunoconjugates comprised “human-
ized” antibodies conjugated to nonim-
munogenic radioisotopes, and more
recently, small highly cytotoxic drugs.
Antibody improvements
Upon recognition of the clinical limita-
tions of murine antibodies, efforts were
undertaken to produce better-tolerated
antibodies which would avoid the induc-
tion of human anti-mouse antibody
(HAMA) response (Reff and Heard,
2001). There are several approaches to
making human or human-like antibodies.
One focuses on reducing the immuno-
genicity of murine IgGs by incorporating
human residues. Initially, mouse-human
IgG chimeras were produced by geneti-
cally engineering the mouse variable
domains onto human constant regions.
The resulting antibodies were approxi-
mately 75% human, displaying circulat-
ing half-lives approaching those of fully
human IgGs. Although chimeric antibod-
ies showed limited immunogenicity in
immunosuppressed patients, in other
clinical settings, they proved highly
immunogenic, preventing repeat dosing
(Kreitman et al., 2001). In subsequent
generations of humanized antibodies,
the number of murine residues was fur-
ther reduced. In one approach, the
murine antibody complementarity-deter-
mining regions (CDRs) that form the anti-
gen binding site as well as key
framework residues of the variable
region are grafted onto a human anti-
body of similar structure. Several anti-
bodies humanized by CDR-grafting are
in the clinic, such as Mylotarg for the
treatment of acute myelogenous
leukemia (AML) (Sievers et al., 2001)
and Herceptin for the treatment of
metastatic breast cancer (Pegram et al.,
1998) with no evidence of immunogenic-
ity. A related method, termed variable
domain resurfacing, uses computer
modeling to identify surface residues in
the variable region of the murine anti-
body, which are then replaced by human
residues. If the substitution results in a
reduction in binding affinity, the residues
are “back-mutated” to murine in various
combinations to reproduce the high affin-
ity binding of the murine antibody. An
antibody that was humanized by variable
domain resurfacing is currently undergo-
ing clinical testing as a cytotoxic drug
conjugate and shows no evidence of
immunogenicity (Tolcher et al., 2003).
Another approach to producing human-
like antibodies exploits the fact that anti-
bodies raised in cynomolgus monkeys
have variable regions virtually indistin-
guishable from those of human IgGs.
Chimeras comprising human constant
domains and monkey variable domains
have been constructed and are undergo-
ing clinical evaluation.
More recently, various technologies
to produce fully human antibodies have
been developed. In the phage display
approach, the antigen of interest is used
to selectively bind phage from highly
complex libraries expressing human
antibody variable regions (Krebs et al.,
2001). Another useful feature of phage
antibody library selection, in addition to
producing human antibodies, is that the
technology does not rely on the immune
repertoire of the mouse, and thus may
allow access to antibodies that would not
be found using traditional hybridoma
technology. The disadvantage of anti-
bodies produced by this method is that
they are often of low affinity, requiring
affinity maturation techniques to improve
antigen binding. Affinity maturation is
accomplished by generating libraries
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consisting of variants of the original anti-
body in which one of the six CDRs is ran-
domly mutated. The new libraries are
then reprobed with antigen to select for
higher affinity variants of the original
antibody. Although time-consuming,
affinity maturation usually identifies anti-
bodies with affinities in the range of
those achievable using hybridoma tech-
nology. More recently, ribosomal and
bacterial surface human antibody display
libraries have been developed.
The goal of raising fully human anti-
bodies in mice has been achieved.
Transgenic mice in which the murine IgG
genes are replaced with the correspond-
ing human genes have been constructed
and shown to generate fully human anti-
gen-specific antibodies in response to
immunization with antigen. The advan-
tage of this approach is that the animals
can be repeatedly immunized with anti-
gen to produce high affinity antibodies.
Immunotoxin conjugates
Although immunotoxin conjugates (ITCs)
have historically given poor clinical results
efforts continue to improve clinical utility
(Kreitman, 2001). The difficulty with
immunotoxin conjugates is 2-fold;
because the toxin is a protein, in most
clinical settings ITCs elicit a human anti-
toxin response (HATA) thus limiting the
efficacy and ability to administer multiple
doses. Most immunotoxins tested in the
clinic to date are comprised of murine sin-
gle-chain variable domain fragments
(scFv) of IgGs, resulting in the appear-
ance of neutralizing HAMAs also.
However, in the case of hematologic
malignancies where patients are often
severely immunosuppressed, there may
be a role for immunotoxin conjugates. For
example, patients with hairy cell leukemia
present with pancytopenia. Consequently,
they respond quite well to an anti-CD22-
pseudomonas exotoxin fragment fusion
(see BL22 in Table 1). In a phase I clinical
trial an 81% overall response rate was
observed with 69% complete remission
(Kreitman et al., 2001). However, even in
this heavily immunosuppressed popula-
tion a subset fail to respond due to the
presence of neutralizing antibodies devel-
oped during the course of treatment or
more rarely, preexisting antitoxin antibod-
ies (Kreitman et al., 2001). In contrast to
patients with hematologic malignancies,
patients with solid tumors are generally
prohibited from receiving multiple doses
of ITC due to the rapid induction of neu-
tralizing antitoxin antibodies (Posey et al.,
2002), severely limiting the amount of
conjugate that can be delivered to the
tumor site. Another drawback to ITCs is
their nonspecific toxicity (Kreitman, 2001).
This appears to stem from damage to the
endothelium, resulting in vascular leak
syndrome (VLS). Recombinant, truncated
toxins show reduced VLS, having primari-
ly hepatic and renal toxicity (Kreitman,
2001). The hepatic toxicity is likely due to
the nonspecific uptake of ITC in Kupffer
cells in the liver resulting in the production
of TNF-α.
Currently, there are a limited number
of immunotoxin conjugates in clinical
development (see Table 1). Recently
reported results for SGN-10, a LewisY-
targeting scFv fused to a pseudomonas
exotoxin fragment, indicate little efficacy
in LewisY-positive metastatic carcinoma
(Posey et al., 2002). Patients also exhib-
ited gastrointestinal dose-limiting toxicity,
modest VLS, and development of HATA.
LMB-9, another LewisY-targeting scFv
fused to truncated pseudomonas exotox-
in similar to SGN10, is also likely to give
disappointing clinical trial results.
Moreover, an earlier version of LMB-9
comprising the parent antibody, B3, cou-
pled to LysPE38, was reported to directly
bind endothelial cells causing antibody-
dependent VSL (Kuan et al., 1995). LMB-
2, while demonstrating some efficacy in
a variety of hematologic malignancies,
also elicits neutralizing HATA and HAMA
in all treated patients with the exception
of 8 patients diagnosed with chronic lym-
phocytic leukemia (CLL) (Kreitman et al.,
2000). A diphtheria toxin fragment target-
ed by fusion to the cytokine IL-2,
denileukin diftitox (Ontak), has been
approved for cutaneous T cell lymphoma
(CTCL), although 98% of the patients
developed HATA by the second treat-
ment dose (Olsen et al., 2001).
Nonetheless, a 30% objective response
was seen with no difference in immuno-
genicity between the responder and
nonresponder groups. Despite this
encouraging clinical response to a
cytokine-targeted toxin, it seems unlikely
that ITCs targeting solid tumors will
demonstrate much clinical efficacy due
to the dosing limitations imposed by their
inherent immunogenicity.
Radioimmunoconjugates
Like immunotoxin conjugates, radioim-
munoconjugates have been under investi-
gation for many years with mixed clinical
results (see Blättler et al., 1996, and refer-
ences therein for review). The β-emitters
Yytrium-90 (90Y) and Iodine-131 (131I) are
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Table 1. Immunotoxin conjugates in clinical development
Immunotoxin conjugate Specificity/drug Cancer Company Development  status
BL22 (RFB4 (dsFv)-PE38) α-CD22 PE38 hairy cell leukemia NCI Phase I
(ds scFv fusion to PE38)
SGN10 (BR96 sFv-PE40/BR96-SCIT) α-LewisY-SCIT breast, colon, prostate, lung Seattle Genetics/Aventis Phase I completed
(SCA)
LMB-9 (B3 (ds scFv)-PE38) α-LewisY-PE38 colorectal, pancreas, esophagus, NCI/IVAX Phase I
(ds scFv fusion to PE38) stomach, breast, NSCLC, GIC, 
bladder, ovarian
LMB-2 (α-Tac(Fv)-PE38) α-CD25-PE38 hematopoietic malignancies NCI Phase I completed
(ds scFv fusion to PE38)
SS1(dsFv)-PE38 α-mesothelin-PE38 mesothelioma, ovarian, NeoPharm Phase I
(ds scFv fusion to PE38) squamous cell NSCLC
SCIT = single chain immunotoxin PE40 (40 kDa truncated pseudomonus exotoxin)
PE38 = 38 kDa truncated pseudomonas exotoxin polypeptide
PE40 = 40 kDa truncated pseudomonas exotoxin polypeptide
NSCLC = non-small-cell lung carcinoma
GIC = gastrointestinal cancer
ds scFv = disulfide-stabilized, single-chain, variable domain fragment
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the most extensively studied isotopes in
radioimmunoconjugates due to their radi-
ologic characteristics, ready availability,
ease of conjugation, and relatively long
half-lives. Despite generally disappointing
clinical results thus far, many clinical trials
are underway with various radioimmuno-
conjugates. The most clinically promising
results have been obtained in treatment of
hematologic cancers due to the radiosen-
sitivity of these tumors and the ability to
deliver the requisite dose for tumor eradi-
cation. The FDA recently approved the
first radioimmunoconjugate, Zevalin (90Y-
anti CD20) for treatment of non-Hodgkin’s
lymphoma (NHL), and Bexxar (131I-anti-
CD20) is under review by the FDA
(Cheson, 2003). Nonetheless, to achieve
robust clinical response, doses often
resulting in severe myeloablation must be
administered. In treatment of solid tumors,
this problem is much more acute. It is gen-
erally not possible to deliver therapeutical-
ly effective doses to solid tumors without
exceeding the maximum tolerated dose
(MTD). However, in certain cases where
radioimmunoconjugates can be selective-
ly delivered to a specific body cavity
where the tumor is located, clinical effica-
cy may be achieved. Intraperitoneal
administration of TheraGyn (90Y-anti-
Muc1) is currently undergoing phase III
clinical testing. Recently, a Phase II clini-
cal trial was completed with an 131I-
labeled anti-tenascin antibody (81C6) in
which the RIC was injected directly into
the surgically created cranial resection
cavity of glioma patients (Reardon et al.,
2002). The average absorbed dose at the
tumor site, while much greater than gen-
erally observed in conventional RIC thera-
py, was somewhat under the theoretical
dose required for the eradication of solid
tumors. Nonetheless, some clinical bene-
fit in terms of median survival was
observed.
Because α particles, by comparison
with β particles, have a much shorter
path length as well as a much higher lin-
ear energy transfer, they are significantly
more selective and potent in killing target
cells (McDevitt and Scheinberg, 2002).
Because of the short path length, little
collateral damage may be inflicted upon
nontarget cells, while a single decay of an
internalized α-emitter passing through
the nucleus can be lethal (Jurcic et al.,
2002; Sgouros et al., 1999). In fact,
dosimetry comparisons of radioisotopes
conjugated to the same antibody showed
up to 1000-fold higher absorbed dose
ratios in target organs with α-emitters
compared with β-emitters (Jurcic et al.,
2002; Sgouros et al., 1999). A compari-
son of the therapeutic efficacies of α-
emitter (211At)- and β-emitter (131I)-labeled
Mov18 antibody recognizing the folate
receptor on OVCAR3 xenografts showed
the 211At conjugate to be superior
(Andersson et al., 2001). However, the
exceedingly short half-life of the α-emit-
ting isotopes with the requisite chemical
properties for conjugation, bismuth-212
(212Bi; 61 min), astatine-211 (211At; 7.2 hr),
and bismuth-213 (213Bi; 45.6 min) pre-
vented their clinical development
(McDevitt et al., 2001). While evidence of
preclinical efficacy in the absence of sig-
nificant toxicity could be obtained
(Andersson et al., 2001; Ballangrud et al.,
2001; Larsen et al., 1998; McDevitt et al.,
2000), as well as patient response in
human clinical trials (Jurcic et al., 2002),
the short half-life of 213Bi limits delivery to
only the most accessible tumor cells,
resulting in limited efficacy. However, a
means to overcome this problem was
recently described (McDevitt et al., 2001)
where a long-lived (t1/2 = 10 days) α-parti-
cle generator, actinium-225 (225Ac) is
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Table 2. Drug immunoconjugates undergoing preclinical/clinical development
Small drug immunoconjugate Specificity/drug (antibody) Cancer Company Development status
Mylotarg; gemtuzumab ozogamicin α-CD33-calicheamycin AML Wyeth-Ayrst/ FDA approval (5/18/00)
(humanized by CDR grafting) CellTech Group
cantuzumab mertansine α-CanAg-DM1 TAP colorectal, pancreatic ImmunoGen Phase I completed
(huC242-DM1/SB-408075) (humanized by resurfacing)
BB-10901/huN901-DM1 α-CD56-DM1 TAP SCLC British Biotech/ in Phase I (UK); Phase I/II (US)
(humanized by CDR grafting) ImmunoGen
MLN2704 α-PSMA-DM1 TAP prostate Milleniuma initiated Phase I (11/21/02)
(formerly MLN591-DM1) (DeImmunized)
bivatuzumab mertansine α-CD44v6-DM1 TAP unspecified Boehringer initiated clinical trials 
(humanized) Ingelheima (10/15/02)
trastuzumab-DM1/Herceptin-DM1 α-Her2/neu-DM1 TAP breast Genentecha preclinical development
(humanized by CDR grafting 
and framework changes)
My9-6-DM1 α-CD33-DM1 TAP AML ImmunoGen preclinical development
(humanized by resurfacing)
SGN-15 α-LewisY-doxorubicin breast, colon, prostate, lung Seattle Genetics/ 3 Phase II clinical trials; breast 
(BMS-182248/BR96-doxorubicin) (chimeric) Aventis completed, will not pursue 
clinical development
SGN-25 (BR96-auristatin E) α-LewisY-auristatin E breast, colon, prostate, lung Seattle Genetics preclinical development
(chimeric)
SGN-35 α-CD30-auristatinE hematologic malignancies, Seattle Genetics preclinical development
lymphomas
aImmunoGen Inc. technology
DM1 = N2′-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine
TAP = tumor activated prodrug
SCLC = small cell lung carcinoma
AML = acute myelogenous leukemia
SCA = single-chain antibody
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attached directly to the targeting anti-
body. 225Ac, once delivered into the tumor
cell, is retained along with its 4 daughter
α-emitting radionuclides (McDevitt et al.,
2001; McDevitt and Scheinberg, 2002). In
several tumor xenograft studies, 225Ac
immunoconjugates have been demon-
strated to be approximately 1000-fold
more potent on a mCi basis than
corresponding 213Bi immunoconjugates
(McDevitt et al., 2001; McDevitt and
Scheinberg, 2002).This can be attributed
to both the long half-life of 225Ac and the
net 4 daughter α particles produced
inside the cell for each internalized 225Ac.
It will be interesting to see whether 225Ac
immunoconjugates, with their longer half-
lives and increased potencies, will be able
to penetrate solid tumors. Nonetheless,
the practical difficulties in manufacturing
and administering radioimmunoconju-
gates may prevent their widespread use
in the clinic.
Drug immunoconjugates
Promising immunoconjugates currently
under clinical investigation consist of
antibodies conjugated to small highly
cytotoxic drugs. Early clinical trials with
antibodies conjugated to clinically useful
drugs such as antifolates, vinca
alkaloids, and approved anthracyclines
such as doxorubicin were disappointing
due to lack of potency (Chari, 1998).
Subsequently, it was hypothesized that
only drugs with potencies approaching
10−11 M would be useful in immunoconju-
gates because a targeting antibody
might be capable of depositing this
amount of drug at a solid tumor site
(Blättler and Chari, 2001). Because
dosimetry studies with radioimmunocon-
jugates have demonstrated that only
0.001 to 0.01 percent of the injected
dose per gram of solid tumor is actually
deposited at the tumor (Sedlacek et al.,
1992), the drug must be stable enough to
be cytotoxic only to antigen-positive
cells. There are a limited number of cyto-
toxic drugs that fulfill this potency and
stability requirement (Blättler and Chari,
2001). Among these are (1) inhibitors of
tubulin polymerization exemplified by the
maytansinoids, dolastatins, auristatin,
and cryptophycin; (2) DNA alkylating
agents like CC-1065 analogs and duo-
carmycin; and (3) the enediyene antibi-
otics such as calicheamicin and
esperamicin which catalyze DNA dou-
ble-strand breaks. More recently,
extremely potent taxoid drugs which
inhibit microtubule depolymerization
have been developed (Ojima et al.,
2002). Only a subset of the available
highly potent cytotoxic drugs have been
linked to antibodies and shown to retain
potency (Chari et al., 1995; Liu et al.,
1996; Ojima et al., 2002; Senter et al.,
2002; Sievers and Linenberger, 2001).
The only antibody-drug conjugate
approved by the FDA to date is gem-
tuzumab ozogamicin (Mylotarg) (Table 2)
for the treatment of patients with CD33-
positive AML in first relapse who are 60
year of age or older and who are not
considered candidates for cytotoxic
chemotherapy (Bross et al., 2001). It is
comprised of a humanized antibody rec-
ognizing the CD33 antigen attached via
a bifunctional hydrazine linker to the
highly potent cytotoxic drug, calicheam-
icin (Sievers and Linenberger, 2001). Of
the patient population treated with gem-
tuzumab ozogamicin, 30% achieve
remission (Sievers et al., 2001). Of con-
cern is the high incidence of severe
myelosuppression in patients treated
with gemtuzumab ozogamicin, which
correlates with the expression of CD33
on normal myeloid and megakaryocytic
precursors. However, CD33 is absent
from pluripotent hematopoietic stem
cells allowing regeneration the full reper-
toire of CD33-positive hematopoietic
cells. Some patients also exhibit hepatic
toxicity with veno-occlusive disease-like
symptoms, possibly due to targeting of
CD33-positive hepatic Kupffer cells
(Sievers and Linenberger, 2001).
However, calicheamicin alone is known
to cause hepatotoxicity in preclinical
models (Bross et al., 2001), suggesting
that the toxicity may be nonspecific
rather than targeted by the antibody.
Antibody-drug conjugates have also
been named tumor-activated prodrugs
(TAPs), since it could be demonstrated
that conjugates of the cytotoxic agent to
antibody rendered it noncytotoxic to cells
devoid of the target antigen. TAP thera-
peutic antibody conjugates (Blättler and
Chari, 2001) are currently under clinical
investigation (see Table 2). These conju-
gates comprise humanized antibodies
linked via a disulfide linker to the highly
potent (IC50 ?10−11 M) maytansine deriv-
ative, DM1. Because the linker is stable
in the blood, the conjugate is nontoxic
until it reaches the tumor site. Specific
antigen binding and internalization result
in release of the drug and potent killing of
tumor cells. In SCID xenograft studies,
with mice bearing large subcutaneous or
disseminated tumors, TAP conjugates
routinely effect cures at doses well below
the MTD under conditions where con-
ventional therapeutics have little tumor
growth inhibitory effect (Blättler and
Chari, 2001; Liu et al., 1996; Ross et al.,
2002; Schwall et al., 2001).
Three phase I trials have been con-
ducted with cantuzumab mertansine for
the treatment of patients with CanAg-
positive malignancies (Helft et al., 2001;
Rowinsky et al., 2002; Tolcher et al.,
2003). CanAg is a tumor-specific carbo-
hydrate epitope found on the Muc1
mucin of most colorectal and pancreatic
tumors as well as a large proportion of
non-small-cell lung, gastric, uterine, and
bladder cancers (Tolcher et al., 2003).
The cantuzumab mertansine conjugate
was well-tolerated with the dose-limiting
toxicity found to be reversible transamini-
tis (elevated liver enzymes). No evidence
of human anti-human antibodies (HAHA)
or human anti-DM1 antibodies (HADA)
was observed. The absence of immuno-
genicity allowed repeated dosing of
patients. In fact, one patient with diffuse
peritoneal carcinomatosis and chronic
ascites obtained a complete resolution of
ascites after 5 weeks of treatment, and
was subsequently treated repeatedly
with no evidence of disease progression.
Several other biological responses were
observed, including partial tumor regres-
sions, stabilization of disease, and
reduction in circulating carcinoembryon-
ic antigen (CEA) levels.
Phase I/II clinical trials have begun
with BB-10901 (huN901-DM1), which
targets CD56 expressed on SCLC and
tumors of neuroendocrine origin. Results
from the first Phase I trial indicate that
huN901-DM1 toxicity is modest, and pre-
liminary evidence of antitumor activity
was observed (Fosella et al., 2002).
Clinical trials with DM1 conjugates tar-
geting prostate-specific membrane anti-
gen (PSMA) for the treatment of prostate
cancer and CD44v6-expressing solid
tumors have also been initiated recently.
In addition to the four TAPs in clinical
trials, others are at the research and pre-
clinical development stage (Table 2).
Trastuzumab-DM1 is a DM1 conjugate to
the Herceptin antibody used to treat
metastatic breast cancer. Trastuzmab-
DM1 is able to eradicate tumors in mod-
els where Herceptin only slows growth
(Schwall et al., 2001). Furthermore, in an
aggressive tumor model in which
Herceptin has no activity, trastuzumab-
DM1 shrinks tumors by more than 90%.
My9-6-DM1 is a DM1 conjugate to a
humanized antibody targeting CD33,
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which is expressed on leukemic blasts of
greater than 80% of AML patients. My9-
6-DM1 treatment of SCID mice bearing
established subcutaneous HL-60 or
THP-1 xenografts resulted in complete
eradication of the tumor at doses well
below the MTD (Lutz et al., 2002).
Other antibody-drug conjugates
under development are BR96-doxoru-
bicin and BR96-auristatin E, both target-
ing LewisY-expressing solid tumors and
anti-CD30-auristatin E (see Table 2).
BR96-doxorubicin has previously been
shown to have marginal efficacy in clini-
cal trials (Ajani et al., 2000; Saleh et al.,
2000;Tolcher, 2000;Tolcher et al., 1999),
while displaying severe upper GI toxicity.
The lack of efficacy is likely due to the
minimal potency of doxorubicin (IC50
?10−8 M). The GI toxicity may be
explained by conjugate binding to LewisY
expressed on normal GI tract epithelium.
The normal tissue binding may also con-
tribute to the lack of efficacy by acting as
an antigen sink, thus compromising the
conjugate delivery to tumor tissue. While
auristatin E, a small molecule with activi-
ty and potency similar to maytansine
(Senter et al., 2002), may be a superior
immunoconjugate effector molecule
compared with doxorubicin, it is not clear
that any LewisY-targeting antibodies will
be useful for conjugate chemotherapeu-
tics due to the GI tract crossreactivity.
The availability of highly potent
drugs with alternate mechanisms of
cytotoxicity may provide an opportunity
for tailoring treatment of a malignancy
with the most active drug for that disease
target, thus optimizing the therapeutic
efficacy. Considerable effort is underway
to develop additional cytotoxic drugs with
stabilities and potencies suitable for con-
jugate development (Blättler and Chari,
2001) to complement the currently avail-
able arsenal. CC-1065, a DNA alkylating
agent, has 1000-fold more cytoxic activi-
ty than other DNA targeting drugs such
as doxorubicin or etoposide. CC-1065-
like derivatives containing thiols have
been synthesized and conjugated to
anti-B4 antibody via a disulfide linkage
(Chari et al., 1995). The resulting conju-
gate, anti-B4-DC1, proved highly potent
both in vitro and in curing SCID mice
bearing a highly aggressive disseminat-
ed lymphoma xenograft. The clinically
useful taxoids, paclitaxel and docetaxel,
do not have sufficient potency to be use-
ful in immunoconjugates (Blättler and
Chari, 2001; Ojima et al., 2002).
However, considerable progress has
been made in the synthesis of second-
generation taxoids with much greater
potency (Kingston et al., 1998; Ojima et
al., 2002). A potent taxoid derivative con-
jugated to an anti-EGFR antibody via a
disulfide linker has been shown to be
active in a xenograft model, completely
eradicating all histopathological evi-
dence of tumor cells (Ojima et al., 2002).
It will be interesting to see whether highly
potent drugs suitable for conjugation can
be developed for additional targets such
as DNA synthesis, metabolic pathways,
and antiapoptotic pathways.
Because of their potency, lack of
immunogenicity in humans, ease of syn-
thesis, chemical stability, and clinical
convenience, small drug immunoconju-
gates represent the most promising
direction for future immunoconjugate
cancer therapy.
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